Yonsei Medical Journal最新文献

{"title":"Epidemiology of Non-Emergent Cancer-Related Emergency Department Visits in Korea between 2016 and 2020.","authors":"Sun Young Lee, Young Sun Ro, Sang Do Shin, Seong Jung Kim, Eujene Jung","doi":"10.3349/ymj.2023.0338","DOIUrl":"10.3349/ymj.2023.0338","url":null,"abstract":"<p><strong>Purpose: </strong>As people living with cancer increase in the aging society, cancer-related emergency department (ED) visits are also increasing. This study aimed to investigate the epidemiologic characteristics of non-emergent cancer-related ED visits using a nationwide ED database.</p><p><strong>Materials and methods: </strong>A cross-sectional study was conducted using the National Emergency Department Information System (NEDIS) database. All cancer-related ED visits between 2016 and 2020 were included. The study outcome was non-emergent ED visits, defined as patients triaged into non-emergent condition at both the time of arrival at ED and discharge from ED and were discharged without hospitalization.</p><p><strong>Results: </strong>Among 1185871 cancer-related ED visits over 5 years, 19.0% (n=225491) were classified as non-emergent visits. While abdominal pain and fever are the top chief complaints in both emergent and non-emergent visits, non-emergent visits had high proportions of abdomen distension (4.8%), ascite (2.4%), and pain in lower limb (2.0%) compared with emergent visits. The cancer types with a high proportion of non-emergent visits were thyroid (32.4%) and prostate cancer (30.4%). Adults compared with children or older adults, female, medical aid insurance, urban/rural ED, direct-in compared with transfer-in, and weekend visit were associated with high odds for non-emergent visits.</p><p><strong>Conclusion: </strong>Approximately 20% of cancer-related ED visits may be potentially non-emergent. A significant number of non-emergent patients visited the ED due to cancer-related symptoms. To improve the quality of care for people living with cancer, the expansion of supportive care resources besides of ED, including active symptom control, is necessary.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 7","pages":"418-426"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.","authors":"Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim","doi":"10.3349/ymj.2023.0263","DOIUrl":"10.3349/ymj.2023.0263","url":null,"abstract":"<p><strong>Purpose: </strong>Nivolumab and regorafenib are second-line therapies for patients with advanced hepatocellular carcinoma (HCC). We aimed to compare the effectiveness of nivolumab and regorafenib.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed patients with HCC treated with nivolumab or regorafenib after sorafenib failure. Progression-free survival (PFS) and overall survival (OS) were analyzed. An inverse probability of treatment weighting using the propensity score (PS) was performed to reduce treatment selection bias.</p><p><strong>Results: </strong>Among the 189 patients recruited, 137 and 52 patients received regorafenib and nivolumab after sorafenib failure, respectively. Nivolumab users showed higher Child-Pugh B patients (42.3% vs. 24.1%) and shorter median sorafenib maintenance (2.2 months vs. 3.5 months) compared to regorafenib users. Nivolumab users showed shorter median OS (4.2 months vs. 7.4 months, <i>p</i>=0.045) than regorafenib users and similar median PFS (1.8 months vs. 2.7 months, <i>p</i>=0.070). However, the median overall and PFS did not differ between the two treatment groups after the 1:1 PS matching (log-rank <i>p</i>=0.810 and 0.810, respectively) and after the stabilized inverse probability of treatment weighting (log-rank <i>p</i>=0.445 and 0.878, respectively). In addition, covariate-adjusted Cox regression analyses showed that overall and PFS did not significantly differ between nivolumab and regorafenib users after 1:1 PS matching and stabilized inverse probability of treatment weighting (all <i>p</i>>0.05).</p><p><strong>Conclusion: </strong>Clinical outcomes of patients treated with nivolumab and regorafenib after sorafenib treatment failure did not differ significantly.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 7","pages":"371-379"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gestational Diabetes and C-Reactive Protein/Albumin Ratio in Pregnancy: A Prospective Study.","authors":"Eda Ureyen Ozdemir, Gul Nihal Buyuk, Esin Merve Erol Koc, Goksun Ipek, Ulku Gurbuz Ozbebek, Muslume Asli Gurun, Necati Hancerliogullari","doi":"10.3349/ymj.2023.0334","DOIUrl":"10.3349/ymj.2023.0334","url":null,"abstract":"<p><strong>Purpose: </strong>The C-reactive protein/albumin ratio (CAR) has been reported as a novel inflammatory marker to assess inflammation. The aim of this study was to compare the levels of CAR as a inflammatory marker in gestational diabetes mellitus (GDM) and non GDM patients.</p><p><strong>Materials and methods: </strong>Eight hundred ten pregnant women who applied to our hospital for routine antenatal screening were included in this prospective case-control study. The patients were divided into two groups, as positive and negative diagnosis of GDM. CAR between groups was compared as the primary outcome using statistical methods.</p><p><strong>Results: </strong>The CAR value was significantly higher in pregnancies with GDM compared to healthy controls [1.07 (0.43-1.89) vs. 0.37 (0.12-0.68), <i>p</i><0.0001]. The Spearman's correlation analysis revealed that the CAR value had a significant positive correlation with all three steps of 75 gr oral glucose tolerance test (<i>p</i><0.0001 for each) and neutrophil to lymphocyte ratio value (<i>p</i>=0.011).</p><p><strong>Conclusion: </strong>Considering that laboratory testing is very simple and inexpensive, CAR is an independent predictor that is clinically easy to use for the development of GDM. This report is the first to show the role of CAR in GDM. However, further studies with larger sample sizes are needed to generalize this comment.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 7","pages":"413-417"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic Single-Site Plus One-Port Myomectomy versus Robotic Single-Site Plus Two-Port Myomectomy: A Propensity Score Matching Analysis.","authors":"Su Hyeon Choi, Seyeon Won, Nara Lee, So Hyun Shim, Mi Kyoung Kim, Mi-La Kim, Yong Wook Jung, Bo Seong Yun, Hye Sun Jun, Seok Ju Seong","doi":"10.3349/ymj.2023.0434","DOIUrl":"10.3349/ymj.2023.0434","url":null,"abstract":"<p><strong>Purpose: </strong>Robotic single-site plus one-port myomectomy (RSOM) was designed to reduce the number of incision sites for greater cosmetic satisfaction of patients while retaining the benefits of conventional robotic multi-site myomectomy (CRM). Robotic single-site plus two-port myomectomy (RSTM) eliminated one port relative to conventional CRM, and RSOM achieved the same advantage with respect to RSTM. This study aimed to compare RSOM with RSTM in terms of their respective methodologies and surgical outcomes.</p><p><strong>Materials and methods: </strong>The medical records of 230 patients who had undergone RSOM and 146 patients who had undergone RSTM were reviewed. The groups' surgical outcomes were compared using propensity score matching (PSM) analysis.</p><p><strong>Results: </strong>In the total data, RSOM had a shorter operative time (135.1±57.4 min vs. 149.9±46.2 min, <i>p</i>=0.009) and a shorter hospital stay (5.2±0.5 days vs. 5.4±0.7 days, <i>p</i>=0.033) relative to RSTM. The PSM analysis showed that there were no statistically significant intergroup differences in the patients' baseline characteristics. Regarding the surgical outcomes, the RSOM group showed shorter operative time (129.2±49.3 min vs. 148.7±46.3 min, <i>p</i>=0.001) compared to the RSTM group.</p><p><strong>Conclusion: </strong>Compared with RSTM, RSOM was associated with shorter operative time. Additionally, more detailed comparative and prospective studies are needed to evaluate RSOM relative to RSTM.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 7","pages":"406-412"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Home-Based Transcranial Direct Current Stimulation on Cognitive Function in Patients with Mild Cognitive Impairment: A Two-Week Intervention.","authors":"Jaesub Park, Kyungmi Chung, Yoonkyung Oh, Kwang Joon Kim, Chang Oh Kim, Jin Young Park","doi":"10.3349/ymj.2023.0430","DOIUrl":"10.3349/ymj.2023.0430","url":null,"abstract":"<p><strong>Purpose: </strong>Repeated transcranial direct current stimulation (tDCS) is expected to have the potential to improve cognitive function in patients with mild cognitive impairment (MCI). We aimed to evaluate the efficacy and safety of at-home tDCS for elderly patients with MCI.</p><p><strong>Materials and methods: </strong>Patients aged 60-80 years, who maintained normal daily living but reported objective memory impairments, were enrolled. Active or sham stimulations were applied to the dorsal frontal cortex (left: anode; right: cathode) at home for 2 weeks. Changes in cognitive function were assessed using visual recognition tasks and the Mini-Mental State Exam (MMSE), and safety and efficacy were assessed using self-reports and a remote monitoring application.</p><p><strong>Results: </strong>Of the 19 participants enrolled, 12 participants were included in the efficacy analysis. Response times and MMSE scores significantly improved after active stimulation compared to the sham stimulation; however, there were no significant differences in the proportion of correct responses. The mean compliance of the efficacy group was 97.5%±4.1%. Three participants experienced burns, but no permanent sequelae remained.</p><p><strong>Conclusion: </strong>This preliminary result suggests that home-based tDCS may be a promising treatment option for MCI patients; however, it requires more attention and technological development to address safety concerns.</p><p><strong>Clinical trial registration: </strong>Clinical Research Information Service (CRIS), KCT0002721.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 6","pages":"341-347"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Carbon Ion Radiotherapy in Solid Tumors: A Systematic Review and Meta-Analysis.","authors":"Ji Eun Yun, Sujin Kim, Keun Young Park, Worlsook Lee","doi":"10.3349/ymj.2023.0439","DOIUrl":"10.3349/ymj.2023.0439","url":null,"abstract":"<p><strong>Purpose: </strong>This systematic review and meta-analysis aimed to investigate the effectiveness of carbon ion radiotherapy (CIRT) compared to that of conventional radiotherapy in patients with various types of solid tumors.</p><p><strong>Materials and methods: </strong>We systematically searched eight electronic databases from inception until August 2022 in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. The comparative effectiveness of the different treatment options was assessed by a random-effects meta-analysis.</p><p><strong>Results: </strong>This review included 34 comparative studies and three treatment groups. Overall, the meta-analysis indicated comparable local control rates between the CIRT and control groups [pooled risk ratio (RR)=1.02, 95% confidence interval (CI) 0.90-1.15]. The local control rate in the CIRT group was higher than that in the photon therapy group, but slightly lower than that in the proton radiation therpy (PRT) group. Additionally, the CIRT group had significantly higher overall survival (OS) (RR=1.19, 95% CI=1.01-1.42) and progression-free survival (PFS) (RR=1.50, 95% CI=1.01-2.21) rates compared to the control group. In the subgroup analysis, survival rates were similar between the CIRT and PRT groups.</p><p><strong>Conclusion: </strong>CIRT was associated with improved toxicity, local tumor control, OS, and PFS compared to conventional treatments. Therefore, CIRT was found to be a safe and effective option for achieving local control in patients with solid tumors.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 6","pages":"332-340"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy Outcomes and Obstetrical Complications of Twin Pregnancies with Endometriosis: A Single-Center Cohort Study.","authors":"Joong Sik Shin, Sujin Kim, Jee Youn Choi, Kirim Hong, Sohyun Shim, Yong Wook Jung, Seok Ju Seong, Hye Sun Jun, Mi-La Kim","doi":"10.3349/ymj.2023.0099","DOIUrl":"10.3349/ymj.2023.0099","url":null,"abstract":"<p><strong>Purpose: </strong>There are many studies regarding the increased relationship between pregnancy outcomes of singleton with endometriosis. However, there was limited evidence of twin pregnancies with endometriosis. This study aimed to compare the pregnancy outcomes and complications in twin pregnancies with or without endometriosis in a single institution.</p><p><strong>Materials and methods: </strong>From January 2011 to July 2022, a retrospective analysis of twin pregnancies was conducted. The endometriosis group included patient with histological or visual confirmation before pregnancy or during cesarean section. Pregnancy outcomes and complications were compared between the two groups.</p><p><strong>Results: </strong>Out of 1714 patients examined, 127 (7.4%) were included in the endometriosis group. Maternal body mass index (BMI) was lower in the endometriosis group (<i>p</i><0.001). There were no significant differences in maternal age, mode of conception, chorionicity, and pregnancy outcomes, such as gestational age at delivery (<i>p</i>=0.835) and the preterm birth rate (<i>p</i>=0.579). The endometriosis group had a significantly higher rate of obstetrical complication: small for gestational age (SGA) <10% (<i>p</i>=0.029). However, after adjustment for BMI, the endometriosis group showed no statistical significance in obstetrical complications, including SGA (adjusted odds ratio, 1.568; 95% confidence interval, 0.984-2.499; <i>p</i>=0.059).</p><p><strong>Conclusion: </strong>Twin pregnancies with endometriosis were not related to adverse effects on pregnancy outcomes and obstetrical complications. To confirm these outcomes, further large prospective studies are required.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 6","pages":"356-362"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association between Social Support, Metabolic Syndrome, and Incidence of Cardio-Cerebrovascular Diseases in Older Adults: The ARIRANG Study.","authors":"Hae-Kweun Nam, Sei-Jin Chang, Chun-Bae Kim, Kyoung Sook Jeong, Sung-Kyung Kim, Dae Ryong Kang, Yong Whi Jeong, Hocheol Lee, Bo Zhao, Sang-Baek Koh","doi":"10.3349/ymj.2023.0455","DOIUrl":"10.3349/ymj.2023.0455","url":null,"abstract":"<p><strong>Purpose: </strong>We investigated the association between social support, metabolic syndrome, and incident cardio-cerebrovascular disease (CCVD) in rural Koreans aged ≥50 years.</p><p><strong>Materials and methods: </strong>We conducted a prospective study using the Korean Genome and Epidemiology Study on Atherosclerosis Risk of Rural Areas in the Korean General Population (KoGES-ARIRANG) dataset. From the baseline of 5169 adults, 1682 participants were finally included according to the exclusion criteria. For outcomes, myocardial infarction, angina, and stroke were included. For independent variables, the social support score and metabolic syndrome were used. Descriptive statistics and multivariate logistic regression were performed to investigate the association among the variables. Paired t-test was conducted to analyze the longitudinal variation of social support scores.</p><p><strong>Results: </strong>During the 6.37 years of median follow-up, 137 participants developed CCVD. The adjusted odds ratio (aOR) of metabolic syndrome with persistently high social support was 2.175 [95% confidence interval (CI): 1.479-3.119]. The aOR of metabolic syndrome with persistently low social support was 2.494 (95% CI: 1.141-5.452). The longitudinal variation of the social support score of persistently high social support group was increased significantly by 4.26±26.32. The score of the persistently low social support group was decreased by 1.34±16.87 with no statistical significance.</p><p><strong>Conclusion: </strong>The presence of metabolic syndrome increases the likelihood of developing onset CCVD. Within the metabolic syndrome positive group, when social support was persistently low, the cohort developed more cardio-cerebrovascular disease compared to the persistently higher social support group. The social support score of the persistently low social support group could be improved through proper intervention. To prevent CCVD, metabolic syndrome components and low social support should be improved in the study participants.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 6","pages":"363-370"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer.","authors":"Hye Yeon Yang, Min Yu Kang, Chang Moo Kang, Woo Jung Lee, Ho Kyoung Hwang","doi":"10.3349/ymj.2023.0399","DOIUrl":"10.3349/ymj.2023.0399","url":null,"abstract":"<p><strong>Purpose: </strong>The microenvironment of pancreatic ductal adenocarcinoma (PDAC) with extensive desmoplastic stroma contributes to aggressive cancer behavior. Angiotensin system inhibitors (ASIs) reduce stromal fibrosis and are a promising therapeutic strategy. The purpose of this study was to examine how ASIs affected the oncological results of patients who had their PDAC removed.</p><p><strong>Materials and methods: </strong>A retrospective assessment was conducted on the clinicopathological and survival data of patients who received curative resection for PDAC at Severance Hospital between January 2012 and December 2019.</p><p><strong>Results: </strong>A total of 410 participants (228 male and 182 female), with a median follow-up period of 12.8 months, were included in this study. Patients were divided into three groups, based on ASI use and history of hypertension: group 1, normotensive and never used ASI (n=210, 51.2%); group 2, ASI non-users with hypertension (n=50, 12.2%); and group 3, ASI users with hypertension (n=150, 36.6%). The three groups did not differ significantly in terms of age, sex, kind of operation, T and N stages, or adjuvant and neoadjuvant therapy. Moreover, there was no discernible difference in disease-free survival between those who used ASI and those who did not (<i>p</i>=0.636). The 5-year overall survival (OS) rates in groups 1, 2, and 3 were 52.6%, 32.3%, and 38.0%, respectively. However, the OS rate of ASI users was remarkably higher than that of non-users (<i>p</i>=0.016).</p><p><strong>Conclusion: </strong>In patients with resected PDAC, ASI is linked to longer survival rates. Furthermore, for individuals with hypertension, ASI in conjunction with conventional chemotherapy may be an easy and successful treatment option.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 6","pages":"324-331"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise Across the Phases of Cancer Survivorship: A Narrative Review.","authors":"Ki-Yong An, Jihee Min, Dong Hoon Lee, Dong-Woo Kang, Kerry S Courneya, Justin Y Jeon","doi":"10.3349/ymj.2023.0638","DOIUrl":"10.3349/ymj.2023.0638","url":null,"abstract":"<p><p>Exercise has long been recognized as an important component of treatment for various diseases. However, the benefits and risks of exercise interventions must be carefully evaluated to ensure the former outweighs the latter. As cancer patients undergo diverse treatment modalities with distinct objectives, a systematic approach partitioning the cancer journey into distinct phases is necessary to inform tailored exercise prescriptions. This narrative review summarizes exercise benefits and mechanisms for cancer patients and survivors across four distinct survivorship periods-before surgery, after surgery and before adjuvant treatment, during nonsurgical treatment (adjuvant and neoadjuvant), and during extended survival. In summary, exercise reduces the risks of complications and declines in physical functioning while improving fatigue, quality of life, and the ability to manage treatment effects. Although additional research is warranted, existing evidence is sufficient to integrate exercise into clinical oncology practice and cancer survivorship programs.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 6","pages":"315-323"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}